Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary K Klein

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Veterinary Clinics of North America. Small Animal Practice|July 11, 2003
Multimodality therapy for head and neck cancerMary K Klein
Journal of the American Veterinary Medical Association|November 2, 2010
Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008)Lynda M Beaver, Gabriele Strottner, Mary K Klein
Veterinary Radiology & Ultrasound : the Official Journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association|June 11, 2009
Evaluation of a head-repositioner and Z-plate system for improved accuracy of dose deliverySarah C Charney, Wendell R Lutz, Mary K Klein, et al.
BMC Veterinary Research|August 26, 2018
Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphomaAbbey R Sadowski, Heather L Gardner, Antonella Borgatti, et al.
Journal of Veterinary Internal Medicine|August 22, 2007
Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled studyAntony S Moore, William S Dernell, Gregory K Ogilvie, et al.
BMC Veterinary Research|June 12, 2015
Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcomaHeather L Gardner, Cheryl A London, Roberta A Portela, et al.
American Journal of Veterinary Research|December 1, 2011
Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumorDeborah A Grosenbaugh, A Timothy Leard, Philip J Bergman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excisionCheryl A London, Phyllis B Malpas, Stacey L Wood-Follis, et al.
Plos One|April 30, 2015
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional StudyCheryl A London, Heather L Gardner, Tamra Mathie, et al.
Science Translational Medicine|August 15, 2014
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responsesNicholas J Roberts, Linping Zhang, Filip Janku, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Veterinary Clinics of North America. Small Animal Practice|July 11, 2003
Multimodality therapy for head and neck cancerMary K Klein
Journal of the American Veterinary Medical Association|November 2, 2010
Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008)Lynda M Beaver, Gabriele Strottner, Mary K Klein
Veterinary Radiology & Ultrasound : the Official Journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association|June 11, 2009
Evaluation of a head-repositioner and Z-plate system for improved accuracy of dose deliverySarah C Charney, Wendell R Lutz, Mary K Klein, et al.
BMC Veterinary Research|August 26, 2018
Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphomaAbbey R Sadowski, Heather L Gardner, Antonella Borgatti, et al.
Journal of Veterinary Internal Medicine|August 22, 2007
Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled studyAntony S Moore, William S Dernell, Gregory K Ogilvie, et al.
BMC Veterinary Research|June 12, 2015
Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcomaHeather L Gardner, Cheryl A London, Roberta A Portela, et al.
American Journal of Veterinary Research|December 1, 2011
Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumorDeborah A Grosenbaugh, A Timothy Leard, Philip J Bergman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excisionCheryl A London, Phyllis B Malpas, Stacey L Wood-Follis, et al.
Plos One|April 30, 2015
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional StudyCheryl A London, Heather L Gardner, Tamra Mathie, et al.
Science Translational Medicine|August 15, 2014
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responsesNicholas J Roberts, Linping Zhang, Filip Janku, et al.
Pageof 1